-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Downgrades TScan Therapeutics to Neutral, Lowers Price Target to $1

Benzinga·09/08/2026 15:16:25
语音播报
HC Wainwright & Co. analyst Andres Y. Maldonado downgrades TScan Therapeutics (NASDAQ:TCRX) from Buy to Neutral and lowers the price target from $7 to $1.